scholarly journals Adjuvant effect of the human metapneumovirus (HMPV) matrix protein in HMPV subunit vaccines

2015 ◽  
Vol 96 (4) ◽  
pp. 767-774 ◽  
Author(s):  
Laetitia Aerts ◽  
Chantal Rhéaume ◽  
Julie Carbonneau ◽  
Sophie Lavigne ◽  
Christian Couture ◽  
...  
Structure ◽  
2014 ◽  
Vol 22 (1) ◽  
pp. 136-148 ◽  
Author(s):  
Cedric Leyrat ◽  
Max Renner ◽  
Karl Harlos ◽  
Juha T. Huiskonen ◽  
Jonathan M. Grimes

Vaccines ◽  
2020 ◽  
Vol 8 (3) ◽  
pp. 365
Author(s):  
Suvi Heinimäki ◽  
Kirsi Tamminen ◽  
Vesa P. Hytönen ◽  
Maria Malm ◽  
Vesna Blazevic

Novel adjuvants present a concern for adverse effects, generating a need for alternatives. Rotavirus inner capsid VP6 protein could be considered a potential candidate, due to its ability to self-assemble into highly immunogenic nanospheres and nanotubes. These nanostructures exhibit immunostimulatory properties, which resemble those of traditional adjuvants, promoting the uptake and immunogenicity of the co-administered antigens. We have previously elucidated an adjuvant effect of VP6 on co-delivered norovirus and coxsackievirus B1 virus-like particles, increasing humoral and cellular responses and sparing the dose of co-delivered antigens. This study explored an immunostimulatory effect of VP6 nanospheres on smaller antigens, P particles formed by protruding domain of a norovirus capsid protein and a short peptide, extracellular matrix protein (M2e) of influenza A virus. VP6 exhibited a notable improving impact on immune responses induced by P particles in immunized mice, including systemic and mucosal antibody and T cell responses. The adjuvant effect of VP6 nanospheres was comparable to the effect of alum, except for induction of superior mucosal and T cell responses when P particles were co-administered with VP6. However, unlike alum, VP6 did not influence M2e-specific immune responses, suggesting that the adjuvant effect of VP6 is dependent on the particulate nature of the co-administered antigen.


2008 ◽  
Vol 89 (11) ◽  
pp. 2698-2708 ◽  
Author(s):  
Aaron Derdowski ◽  
Timothy R. Peters ◽  
Nancy Glover ◽  
Ray Qian ◽  
Thomas J. Utley ◽  
...  

Human metapneumovirus (HMPV) is a recently discovered paramyxovirus of the subfamily Pneumovirinae, which also includes avian pneumovirus and human respiratory syncytial virus (HRSV). HMPV is an important cause of respiratory disease worldwide. To understand early events in HMPV replication, cDNAs encoding the HMPV nucleoprotein (N), phosphoprotein (P), matrix protein (M), M2-1 protein and M2-2 protein were cloned from cells infected with the genotype A1 HMPV wild-type strain TN/96-12. HMPV N and P were shown to interact using a variety of techniques: yeast two-hybrid assays, co-immunoprecipitation and fluorescence resonance energy transfer (FRET). Confocal microscopy studies showed that, when expressed individually, fluorescently tagged HMPV N and P exhibited a diffuse expression pattern in the host-cell cytoplasm of uninfected cells but were recruited to cytoplasmic viral inclusion bodies in HMPV-infected cells. Furthermore, when HMPV N and P were expressed together, they also formed cytoplasmic inclusion-like complexes, even in the absence of viral infection. FRET microscopy revealed that HMPV N and P interacted directly within cytoplasmic inclusion-like complexes. Moreover, it was shown by yeast two-hybrid analysis that the N-terminal 28 aa are required for the recruitment to and formation of cytoplasmic inclusions, but are dispensable for binding to HMPV P. This work showed that HMPV N and P proteins provide the minimal viral requirements for HMPV inclusion body formation, which may be a distinguishing characteristic of members of the subfamily Pneumovirinae.


PLoS ONE ◽  
2011 ◽  
Vol 6 (3) ◽  
pp. e17818 ◽  
Author(s):  
Audrey Bagnaud-Baule ◽  
Olivier Reynard ◽  
Magali Perret ◽  
Jean-Luc Berland ◽  
Mimoun Maache ◽  
...  

2022 ◽  
Vol 12 ◽  
Author(s):  
Akitsu Masuda ◽  
Jae Man Lee ◽  
Takeshi Miyata ◽  
Hiroaki Mon ◽  
Keita Sato ◽  
...  

The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is causing a spread of coronavirus disease 2019 (COVID-19) globally. In order to end the COVID-19 pandemic, an effective vaccine against SARS-CoV-2 must be produced at low cost and disseminated worldwide. The spike (S) protein of coronaviruses plays a pivotal role in the infection to host cells. Therefore, targeting the S protein is one of the most rational approaches in developing vaccines and therapeutic agents. In this study, we optimized the expression of secreted trimerized S protein of SARS-CoV-2 using a silkworm-baculovirus expression vector system and evaluated its immunogenicity in mice. The results showed that the S protein forming the trimeric structure was the most stable when the chicken cartilage matrix protein was used as the trimeric motif and could be purified in large amounts from the serum of silkworm larvae. The purified S protein efficiently induced antigen-specific antibodies in mouse serum without adjuvant, but its ability to induce neutralizing antibodies was low. After examining several adjuvants, the use of Alum adjuvant was the most effective in inducing strong neutralizing antibody induction. We also examined the adjuvant effect of paramylon from Euglena gracilis when administered with the S protein. Our results highlight the effectiveness and suitable construct design of the S protein produced in silkworms for the subunit vaccine development against SARS-CoV-2.


Author(s):  
Cedric Leyrat ◽  
Max Renner ◽  
Jonathan M Grimes

2021 ◽  
Vol 67 (10/2021) ◽  
Author(s):  
Nobuhisa Ishiguro ◽  
Yasushi Akutsu ◽  
Katsuki Azuma ◽  
Motoharu Yonekawa ◽  
Daisuke Sato ◽  
...  

2008 ◽  
Vol 82 (23) ◽  
pp. 11813-11823 ◽  
Author(s):  
Bao-Zhong Wang ◽  
Fu-Shi Quan ◽  
Sang-Moo Kang ◽  
Jadranka Bozja ◽  
Ioanna Skountzou ◽  
...  

ABSTRACT We have designed a membrane-anchored form of the Toll-like receptor 5 ligand flagellin, the major proinflammatory determinant of enteropathogenic Salmonella, which was found to be glycosylated and expressed on cell surfaces. A chimeric influenza virus-like particle (cVLP) vaccine candidate containing A/PR8/34 (H1N1) hemagglutinin (HA), matrix protein (M1), and the modified flagellin as a molecular adjuvant was produced. The immunogenicity, including the serum antibody levels and cellular immune responses, and the protective efficacy against homologous and heterologous live virus challenge of the resulting VLPs were tested after intramuscular administration in a mouse model. The results demonstrated that flagellin-containing VLPs elicited higher specific immunoglobulin G (IgG) responses than standard HA and M1 VLPs, indicating the adjuvant effect of flagellin. Enhanced IgG2a and IgG2b but not IgG1 responses were observed with flagellin-containing VLPs, illuminating the activation of Th1 class immunity. The adjuvant effects of flagellin were also reflected by enhanced specific cellular responses revealed by the secretion of cytokines by freshly isolated splenocyte cultures when stimulated with pools of major histocompatibility complex class I or II peptides. When immunized mice were challenged with homologous live PR8 virus, complete protection was observed for both the standard and cVLP groups. However, when a heterosubtypic A/Philippines (H3N2) virus was used for challenge, all of the standard VLP group lost at least 25% of body weight, reaching the experimental endpoint. In contrast, for the cVLP group, 67% of mice survived the challenge infection. These results reveal that cVLPs designed by incorporating flagellin as a membrane-anchored adjuvant induce enhanced cross-protective heterosubtypic immune responses. They also indicate that such cVLP vaccines are a promising new approach for protection against pandemic influenza viruses.


Sign in / Sign up

Export Citation Format

Share Document